157 related articles for article (PubMed ID: 27014922)
1. Repurposing the Clinically Efficacious Antifungal Agent Itraconazole as an Anticancer Chemotherapeutic.
Pace JR; DeBerardinis AM; Sail V; Tacheva-Grigorova SK; Chan KA; Tran R; Raccuia DS; Wechsler-Reya RJ; Hadden MK
J Med Chem; 2016 Apr; 59(8):3635-49. PubMed ID: 27014922
[TBL] [Abstract][Full Text] [Related]
2. Structure-Activity Relationships for Itraconazole-Based Triazolone Analogues as Hedgehog Pathway Inhibitors.
Pace JR; Teske KA; Chau LQ; Dash RC; Zaino AM; Wechsler-Reya RJ; Hadden MK
J Med Chem; 2019 Apr; 62(8):3873-3885. PubMed ID: 30896941
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of hedgehog signaling by stereochemically defined des-triazole itraconazole analogues.
Wen J; Teske KA; Kyle Hadden M
Bioorg Med Chem Lett; 2020 Jan; 30(2):126794. PubMed ID: 31761657
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationship study of itraconazole, a broad-range inhibitor of picornavirus replication that targets oxysterol-binding protein (OSBP).
Bauer L; Ferla S; Head SA; Bhat S; Pasunooti KK; Shi WQ; Albulescu L; Liu JO; Brancale A; van Kuppeveld FJM; Strating JRPM
Antiviral Res; 2018 Aug; 156():55-63. PubMed ID: 29807040
[TBL] [Abstract][Full Text] [Related]
5. The relationship between the success rate of empirical antifungal therapy with intravenous itraconazole and clinical parameters, including plasma levels of itraconazole, in immunocompromised patients receiving itraconazole oral solution as prophylaxis: a multicenter, prospective, open-label, observational study in Korea.
Kim JS; Cheong JW; Kim YK; Park J; Mun YC; Kang HJ; Yi HG; Lee JH; Kim YS; Ryoo HM; Kim SH; Kim HY; Kim JY; Lee DG; Kim HG; Kim H; Joo YD; Min YH
Ann Hematol; 2014 Jan; 93(1):33-42. PubMed ID: 23807252
[TBL] [Abstract][Full Text] [Related]
6. [The therapeutic effects of itraconazole, a new triazole antifungal agent, for experimental fungal infections].
Uchida K; Yamaguchi H; Shibuya K
Jpn J Antibiot; 1991 May; 44(5):588-99. PubMed ID: 1652657
[TBL] [Abstract][Full Text] [Related]
7. Stereospecific metabolism of itraconazole by CYP3A4: dioxolane ring scission of azole antifungals.
Peng CC; Shi W; Lutz JD; Kunze KL; Liu JO; Nelson WL; Isoherranen N
Drug Metab Dispos; 2012 Mar; 40(3):426-35. PubMed ID: 22106171
[TBL] [Abstract][Full Text] [Related]
8. Formulation and evaluation of itraconazole liposomes for Hedgehog pathway inhibition.
Pace JR; Jog R; Burgess DJ; Hadden MK
J Liposome Res; 2020 Sep; 30(3):305-311. PubMed ID: 31576768
[TBL] [Abstract][Full Text] [Related]
9. Improved antifungal activity of itraconazole-loaded PEG/PLA nanoparticles.
Essa S; Louhichi F; Raymond M; Hildgen P
J Microencapsul; 2013; 30(3):205-17. PubMed ID: 22894166
[TBL] [Abstract][Full Text] [Related]
10. Amphotericin B, alone or followed by itraconazole therapy, is effective in the control of experimental disseminated sporotrichosis by Sporothrix brasiliensis.
Ishida K; de Castro RA; Borba Dos Santos LP; Quintella LP; Lopes-Bezerra LM; Rozental S
Med Mycol; 2015 Jan; 53(1):34-41. PubMed ID: 25306202
[TBL] [Abstract][Full Text] [Related]
11. Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth.
Kim J; Tang JY; Gong R; Kim J; Lee JJ; Clemons KV; Chong CR; Chang KS; Fereshteh M; Gardner D; Reya T; Liu JO; Epstein EH; Stevens DA; Beachy PA
Cancer Cell; 2010 Apr; 17(4):388-99. PubMed ID: 20385363
[TBL] [Abstract][Full Text] [Related]
12. Plasma concentration of itraconazole in patients receiving chemotherapy for hematological malignancies: the effect of famotidine on the absorption of itraconazole.
Kanda Y; Kami M; Matsuyama T; Mitani K; Chiba S; Yazaki Y; Hirai H
Hematol Oncol; 1998 Mar; 16(1):33-7. PubMed ID: 9821410
[TBL] [Abstract][Full Text] [Related]
13. Studies on itraconazole delivery and pharmacokinetics in mallard ducks (Anas platyrhynchos).
Tell LA; Craigmill AL; Clemons KV; Sun Y; Laizure SC; Clifford A; Ina JH; Nugent-Deal JP; Woods L; Stevens DA
J Vet Pharmacol Ther; 2005 Jun; 28(3):267-74. PubMed ID: 15953200
[TBL] [Abstract][Full Text] [Related]
14. NanoCluster Itraconazole Formulations Provide a Potential Engineered Drug Particle Approach to Generate Effective Dry Powder Aerosols.
Pornputtapitak W; El-Gendy N; Berkland C
J Aerosol Med Pulm Drug Deliv; 2015 Oct; 28(5):341-52. PubMed ID: 25679514
[TBL] [Abstract][Full Text] [Related]
15. [In vitro antifungal activity of itraconazole, a new triazole antifungal agent, against clinical isolates from patients with dermatomycoses].
Uchida K; Hosaka J; Aoki K; Yamaguchi H
Jpn J Antibiot; 1991 May; 44(5):571-9. PubMed ID: 1652655
[TBL] [Abstract][Full Text] [Related]
16. Toxoplasma gondii: fluconazole and itraconazole activity against toxoplasmosis in a murine model.
Martins-Duarte ES; Lemgruber L; de Souza W; Vommaro RC
Exp Parasitol; 2010 Apr; 124(4):466-9. PubMed ID: 20045696
[TBL] [Abstract][Full Text] [Related]
17. Repurposed itraconazole for use in the treatment of malignancies as a promising therapeutic strategy.
Li CL; Fang ZX; Wu Z; Hou YY; Wu HT; Liu J
Biomed Pharmacother; 2022 Oct; 154():113616. PubMed ID: 36055112
[TBL] [Abstract][Full Text] [Related]
18. Variability of Hydroxy-Itraconazole in Relation to Itraconazole Bloodstream Concentrations.
Wiederhold NP; Schwartz IS; Patterson TF; Thompson GR
Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33468480
[TBL] [Abstract][Full Text] [Related]
19. Induction of cytochrome P450 1A1 by ketoconazole and itraconazole but not fluconazole in murine and human hepatoma cell lines.
Korashy HM; Shayeganpour A; Brocks DR; El-Kadi AO
Toxicol Sci; 2007 May; 97(1):32-43. PubMed ID: 17283379
[TBL] [Abstract][Full Text] [Related]
20. Itraconazole suppresses an elicitation phase of a contact hypersensitivity reaction.
Ausaneya U; Kawada A; Aragane Y
J Invest Dermatol; 2006 May; 126(5):1028-35. PubMed ID: 16514416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
